What is the appropriate tapering schedule for methotrexate in a patient with ocular sarcoidosis who started at 15 mg weekly and has been reduced to 5 mg weekly after one year?

Methotrexate Tapering in Ocular Sarcoidosis

Continue methotrexate at 5 mg weekly with close monitoring, and consider attempting further taper by 2.5 mg every 2-4 weeks only if disease remains completely controlled, recognizing that 80% of patients require reinstitution of therapy after methotrexate withdrawal.

Rationale for Continued Low-Dose Therapy

The current dose of 5 mg weekly represents a minimal maintenance dose after successful tapering from 15 mg over one year. While guidelines for rheumatic diseases suggest starting doses of 10-15 mg weekly 1, the goal once remission is achieved is to use the lowest maintenance dose to control the condition 2. Your patient has successfully reached this minimal effective dose.

Evidence Against Rapid Discontinuation

Withdrawal of methotrexate therapy after 2 years for chronic sarcoidosis was associated with an 80% re-institution of systemic therapy 3. This high relapse rate is critical—most patients cannot maintain disease control after stopping methotrexate, even after prolonged treatment periods. The ERS guidelines specifically note that relapse of symptomatic disease occurs in a significant number of patients upon withdrawal of therapy after 1-2 years 3.

Tapering Strategy if Attempting Further Reduction

If disease activity remains completely suppressed at 5 mg weekly for at least 3-6 months with:

• No inflammatory markers on exam
• Stable visual function
• No systemic symptoms

Then consider:

Taper by 2.5 mg every 2-4 weeks (following the rheumatology guideline approach 1)

• Reduce to 2.5 mg weekly for 2-4 weeks
• Monitor closely for disease flare with monthly ophthalmologic examination
• Check CBC, liver enzymes, and creatinine every 1-3 months 1

If attempting complete discontinuation:

• Maintain 2.5 mg weekly for at least 3 months before stopping
• Continue monitoring every 1-2 months for 6 months after discontinuation
• Have a low threshold to restart therapy at first sign of recurrence

Critical Monitoring Parameters

During any taper:

• Monthly ophthalmologic examination for the first 3 months after each dose reduction
• Laboratory monitoring every 1-3 months: CBC, AST/ALT, creatinine 1
• Clinical assessment for systemic symptoms at each visit

Common Pitfalls to Avoid

1. Tapering too rapidly: The 5 mg increment used in rheumatology guidelines applies to higher doses. At 5 mg weekly, use 2.5 mg decrements maximum.

2. Assuming cure: Sarcoidosis is a chronic relapsing disease. The 80% relapse rate after methotrexate withdrawal means most patients need indefinite low-dose therapy 3.

3. Stopping monitoring: Even at low doses, continue regular laboratory surveillance for hepatotoxicity and myelosuppression 1.

4. Missing early relapse: Ocular inflammation can cause irreversible damage. Monthly eye exams during taper are essential.

Alternative Approach: Maintenance Therapy

Given the 80% relapse rate, strongly consider maintaining 5 mg weekly indefinitely rather than attempting complete discontinuation. Methotrexate has an acceptable safety profile for long-term use 1, and the risk of vision-threatening relapse in ocular sarcoidosis may outweigh the minimal additional benefit of complete drug withdrawal.

Ensure continued folic acid supplementation of at least 5 mg weekly 1, 2 to minimize toxicity during ongoing therapy.